` XTLB (X T L Biopharmaceuticals Ltd) vs Tel Aviv 355 Comparison - Alpha Spread

X
XTLB
vs
T
Tel Aviv 355

Over the past 12 months, XTLB has underperformed Tel Aviv 355, delivering a return of -57% compared to the Tel Aviv 355's +51% growth.

Stocks Performance
XTLB vs Tel Aviv 355

Loading
XTLB
Tel Aviv 355
Add Stock
www.alphaspread.com

Performance Gap
XTLB vs Tel Aviv 355

Loading
XTLB
Tel Aviv 355
Difference
www.alphaspread.com

Performance By Year
XTLB vs Tel Aviv 355

Loading
XTLB
Tel Aviv 355
Add Stock

Competitors Performance
X T L Biopharmaceuticals Ltd vs Peers

Tel Aviv 355
XTLB
ABBV
AMGN
GILD
VRTX
Add Stock

X T L Biopharmaceuticals Ltd
Glance View

Market Cap
36.1m ILS
Industry
Biotechnology

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). hCDR1 is a peptide (short protein) that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

XTLB Intrinsic Value
Not Available
X
Back to Top